Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is offering concessions to U.S. healthcare providers to switch patients to the extended-release formulation.

You may also be interested in...



Sanofi Suit Triggers 30-Month Stay Of FDA Action On Barr’s Ambien CR ANDA

Sanofi-Aventis filed a patent infringement suit against Barr on April 5 over the controlled release form of zolpidem.

Sanofi Suit Triggers 30-Month Stay Of FDA Action On Barr’s Ambien CR ANDA

Sanofi-Aventis filed a patent infringement suit against Barr on April 5 over the controlled release form of zolpidem.

Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share

Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.

Related Content

Topics

UsernamePublicRestriction

Register

PS064774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel